Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)

Biomaterials

Volumn 34, Issue 36, 2013, Pages 9115-9123

  Pan, Li Qiang ^a   Wang, Hai Bin ^a   Lai, Jun ^a   Xu, Ying Chun ^a   Zhang, Chen ^a   Chen, Shu Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antitumor agent; Glycosylation site; PEG TRAIL; Protein delivery; Site specific PEGylation

Indexed keywords

ANTI-TUMOR AGENTS; GLYCOSYLATION SITES; PEG-TRAIL; PEGYLATION; PROTEIN DELIVERY;

AMINO ACIDS; CELL CULTURE; CELL DEATH; DRUG DELIVERY; ESTERIFICATION; ETHYLENE GLYCOL; GLYCOPROTEINS; GLYCOSYLATION; LIGANDS; MACROPHAGES;

MOTION PICTURE EXPERTS GROUP STANDARDS;

CYSTEINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GLYCOSYLATION; IN VITRO STUDY; MALE; MOUSE; MUTANT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANTITUMOR AGENT; GLYCOSYLATION SITE; PEG-TRAIL; PROTEIN DELIVERY; SITE-SPECIFIC PEGYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CIRCULAR DICHROISM; CYSTEINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; KIDNEY; LIVER; MICE; MICE, INBRED BALB C; MUTATION; NEOPLASMS; POLYETHYLENE GLYCOLS; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 84883780115     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.020     Document Type: Article

References (29)

1. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997, 7:813-820.
2. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997, 7:821-830.
3. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001, 7:954-960.
4. Spierings D.C., de Vries E.G., Timens W., Groen H.J., Boezen H.M., de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003, 9:3397-3405.
5. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., Rijcken F.E., Hollema H., de Vries E.G., et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. JPathol 2003, 200:327-335.
6. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
7. Kelley S.K., Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004, 4:333-339.
8. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999, 59:734-741.
9. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. JClin Invest 1999, 104:155-162.
10. Gliniak B., Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity invivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999, 59:6153-6158.
11. Marini P., Schmid A., Jendrossek V., Faltin H., Daniel P.T., Budach W., et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005, 5:5.
12. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of invivo efficacy, pharmacokinetics, and safety. JPharmacol Exp Ther 2001, 299:31-38.
13. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7:383-385.
14. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Buchler P., Haas T.L., et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006, 12:2640-2646.
15. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. JBiol Chem 1996, 271:12687-12690.
16. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand invivo. Nat Med 1999, 5:157-163.
17. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
18. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003, 55:1293-1302.
19. Levy Y., Hershfield M.S., Fernandez-Mejia C., Polmar S.H., Scudiery D., Berger M., et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. JPediatr 1988, 113:312-317.
20. Jiang H.H., Kim T.H., Lee S., Chen X., Youn Y.S., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 2011, 32:8529-8537.
21. Kim T.H., Youn Y.S., Jiang H.H., Lee S., Chen X., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjug Chem 2011, 22:1631-1637.
22. Gonelli A., Radillo O., Drioli S., Rimondi E., Secchiero P., Maria Bonora G. Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Invest New Drugs 2012, 30:828-832.
23. Chae S.Y., Kim T.H., Park K., Jin C.H., Son S., Lee S., et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010, 9:1719-1729.
24. Kinstler O.B., Brems D.N., Lauren S.L., Paige A.G., Hamburger J.B., Treuheit M.J. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 1996, 13:996-1002.
25. Bodmer J.L., Meier P., Tschopp J., Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. JBiol Chem 2000, 275:20632-20637.
26. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicoll J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
27. Pan L.Q., Wang H.B., Xie Z.M., Li Z.H., Tang X.J., Xu Y.C., et al. Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery. Adv Mater 2013, 10.1002/adma.201301385.
28. Pan L.Q., Xie Z.M., Tang X.J., Wu M., Wang F.R., Naranmandura H., et al. Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1. Appl Microbiol Biotechnol 2013, 97:7253-7264.
29. Goodson R.J., Katre N.V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (N Y) 1990, 8:343-346.